Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand the purpose and risks of the study, and who are willing to provide signed, dated consent to participate and to share relevant health information
• People who speak and read English fluently
• People aged 18 to 89 years old (inclusive)
• People with normal hearing and vision, or hearing and vision that is corrected to normal (for example, with hearing aids or glasses)
• People who have received a clinical diagnosis of Mild Cognitive Impairment (MCI) or Mild Alzheimer's Disease, based on specific diagnostic criteria used by the trial
• People who have a study partner available to participate alongside them for the full duration of the trial
• People who carry at least one copy of a specific gene variant called APOE ε4
• People whose calculated risk score is above 4, based on a specific risk assessment method developed by researchers in 2017
• People who take niacin (vitamin B3) — including through a vitamin supplement — at a dose above 200mg per day, and who have completed a two-week period of stopping that supplement before joining the trial

Who may not be able to join:

• People with a serious or unstable medical or neurological condition that could affect thinking or memory, as assessed by the study doctor
• People who have had an unstable mood or anxiety disorder within the six months before screening, as assessed by the study doctor
• People with a lifetime history of a psychotic disorder, such as Schizophrenia or Schizoaffective Disorder, as assessed by the study doctor
• People who have been diagnosed with a mitochondrial disorder
• People who have any medical condition or implant that makes MRI scanning unsafe for them
• People who have had a known allergic reaction or sensitivity to NR (Nicotinamide Riboside, the supplement being studied in this trial)
• People who have had a mini-stroke (transient ischemic attack) or stroke within the past year
• People with a history of alcohol or substance misuse within the past year, as assessed by the study doctor and a urine test
• People with a history of a moderate or severe head injury, as defined by DSM-5 medical criteria
• People who have had a seizure within the past 10 years
• People currently taking medications known to affect thinking or memory, including certain sedatives, painkillers, antipsychotics, or antihistamines (confirm with trial site for the full list)
• People whose dose of any psychiatric medication has changed within four weeks before the screening visit
• People who have previously used L-DOPA, any Parkinson's disease medication, or any anti-amyloid immunotherapy treatment
• People currently using supplements or medications intended to support mitochondrial function or act as antioxidants, such as carnitine, creatine, Co-Q10, N-acetyl cysteine, or pramipexole
• People who have started or changed their dose of Alzheimer's medications (such as acetylcholinesterase inhibitors or memantine) within four weeks before the screening visit
• People who have used prescription opioid (narcotic) medications within four weeks before the screening visit
• People who are currently pregnant or breastfeeding
• People who have used niacin or a niacin-containing vitamin supplement at a dose above 200mg within the two weeks before the study visit, and who have not completed the required two-week wash-out period

Important: Always verify eligibility with the trial site directly before applying.